Search

Search Results

• Optimizing bexarotene therapy for cutaneous T-cell lymphoma

  M Duvic

  2009-06-10

  https://doi.org/10.4081/hmr.v2i13.495

  249

  PDF: 733

• Optimizing denileukin diftitox (Ontak®) therapy

  M Duvic

  2009-06-10

  https://doi.org/10.4081/hmr.v2i13.491

  187

  PDF: 742

• From cell biology to therapy: forodesine

  M Duvic

  2009-06-23

  https://doi.org/10.4081/hmr.v2i5.746

  409

  PDF: 766

• A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma

  MG Bernengo, F Vanaclocha, M Duvic, T Kuzel, F Kerdel, L Pinter-Brown, A Bosly, C Okada, D Breneman, PL Zinzani, J Becker, L Hughey, M Ardaiz, J Zain, L Zhang

  2009-06-23

  https://doi.org/10.4081/hmr.v2i5.725

  203

  PDF: 202

• Histone deacetylase inhibitors: SAHA (Vorinostat). A treatment option for advanced cutaneous T-cell lymphoma

  M Duvic

  2009-06-23

  https://doi.org/10.4081/hmr.v2i5.724

  261

  PDF: 2326

• Innovative treatments: bexarotene

  M Duvic

  2009-06-11

  https://doi.org/10.4081/hmr.v3i1.544

  205

  PDF: 338

• Epigenetic approaches. Histone deacetylase inhibitors: vorinostat. A new treatment option for advanced cutaneous T-cell lymphoma

  M Duvic

  2009-06-11

  https://doi.org/10.4081/hmr.v3i1.525

  267

  PDF: 352